Clinical Trial Update: Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of a monovalent chimpanzee adenoviral-vectored vaccine targeting Sudan ebolavirus has completed in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Sudan Virus Disease

Drugs mentioned

• Monovalent chimpanzee adenoviral vectored Sudan Ebolavirus vaccine (Chimpanzee adenovirus vector-based Sudan ebolavirus vaccine)

Snippet

Sponsor: Albert B. Sabin Vaccine Institute | Conditions: Ebola Sudan Virus Disease | Phase 2 | Status: COMPLETED